

1 **Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a** 2 **population level in Germany**

3
4 Alex Dulovic (PhD)^{1,#}, Barbora Kessel (PhD)^{2,#}, Manuela Harries (MSc)^{2,#}, Matthias Becker (MSc)¹,
5 Julia Ortmann (BSc)², Johanna Griesbaum¹, Jennifer Jüngling¹, Daniel Junker (MSc)¹, Pilar Hernandez
6 (PhD)², Daniela Gornyk (MSc)², Stephan Glöckner (PhD)², Vanessa Melhorn (PhD)², Stefanie Castell
7 (MD)², Jana-Kristin Heise (MSc)², Yvonne Kemmling (MD)², Torsten Tonn (Prof)³, Kerstin Frank
8 (PhD)³, Thomas Illig (Prof)⁴, Norman Klopp (PhD)⁴, Neha Warikoo (PhD)², Angelika Rath², Christina
9 Suckel (MSc)², Anne Ulrike Marzian², Nicole Grupe², Philipp D. Kaiser (PhD)¹, Bjoern Traenkle
10 (PhD)¹, Ulrich Rothbauer (Prof)^{1,5}, Tobias Kerrinnes (PhD)⁶, Gérard Krause (Prof)^{2,7,8}, Berit Lange
11 (MD)^{2,8,§,*}, Nicole Schneiderhan-Marra (PhD)^{1,§,*}, Monika Strengert (PhD)^{2,7,§,*}

12
13 ¹ NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
14 ² Helmholtz Centre for Infection Research, Braunschweig, Germany
15 ³ Institute of Transfusion Medicine and Immunohematology, German Red Cross, Plauen, Germany
16 ⁴ Hannover Unified Biobank, Hannover Medical School, Hannover, Germany
17 ⁵ Pharmaceutical Biotechnology, University of Tübingen, Germany
18 ⁶ Helmholtz Institute for RNA-based Infection Research, Würzburg, Germany
19 ⁷ TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover
20 Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany
21 ⁸ German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany

22
23 #, § these authors contributed equally to this work.

24 * corresponding authors.

25
26 Corresponding authors contact details:

27 Monika Strengert, Phone number: +49(0)53161813103, Email address: [monika.strengert@helmholtz-](mailto:monika.strengert@helmholtz-hzi.de)
28 [hzi.de](mailto:monika.strengert@helmholtz-hzi.de), Postal address: Inhoffenstraße 7, 38124 Braunschweig, Germany.

29 Berit Lange, Phone number: +49(0)53161813110, Email address: berit.lange@helmholtz-hzi.de, Postal
30 address: Inhoffenstraße 7, 38124 Braunschweig, Germany.

31 Nicole Schneiderhan-Marra, Phone number: +49(0)712151530815, Email address:
32 nicole.schneiderhan@nmi.de, Postal address: Markwiesenstraße 55, 72770 Reutlingen, Germany.

33

34 **Abstract**

35 ***Background***

36 While SARS-CoV-2 vaccinations were successful in decreasing COVID-19 caseloads, recent increases
37 in SARS-CoV-2 infections have led to questions about duration and quality of the subsequent immune
38 response. While numerous studies have been published on immune responses triggered by vaccination,
39 these often focused on the initial peak response generated in specific population subgroups (e.g.
40 healthcare workers or immunocompromised individuals) and have often only examined the effects of
41 one or two different immunisation schemes.

42 ***Methods and Findings***

43 We analysed serum samples from participants of a large German seroprevalence study (MuSPAD) who
44 had received all available vaccines and dose schedules (mRNA-1273, BNT162b2, AZD1222,
45 Ad26.CoV2S.2 or a combination of AZD1222 plus either mRNA-1273 or BNT162b2). Antibody titers
46 against various SARS-CoV-2 antigens and ACE2 binding inhibition against SARS-CoV-2 wild-type
47 and the Alpha, Beta, Gamma and Delta variants of concern were analysed using a previously published
48 multiplex immunoassay MULTICOV-AB and an ACE2-RBD competition assay. Among the different
49 vaccines and their dosing regimens, homologous mRNA-based or heterologous prime-boost vaccination
50 produced significantly higher antibody responses than vector-based homologous vaccination.
51 Ad26.CoV2S.2 performance was significantly reduced, even compared to AZD1222, with 91.67% of
52 samples being considered non-responsive for ACE2 binding inhibition. mRNA-based vaccination
53 induced a higher ratio of RBD- and S1-targeting antibodies than vector-based vaccination, which
54 resulted in an increased proportion of S2-targeting antibodies. Previously infected individuals had a
55 robust immune response once vaccinated, regardless of which vaccine they received. When examining
56 antibody kinetics post-vaccination after homologous immunisation regimens, both titers and ACE2
57 binding inhibition peaked approximately 28 days post-vaccination and then decreased as time increased.

58 ***Conclusions***

59 As one of the first and largest population-based studies to examine vaccine responses for all currently
60 available immunisation schemes in Germany, we found that homologous mRNA or heterologous
61 vaccination elicited the highest immune responses. The high percentage of non-responders for
62 Ad26.CoV2.S requires further investigation and suggests that a booster dose with an mRNA-based
63 vaccine may be necessary. The high responses seen in recovered and vaccinated individuals could aid
64 future dose allocation, should shortages arise for certain manufacturers. Given the role of RBD- and S1-
65 specific antibodies in neutralising SARS-CoV-2, their relative over-representation after mRNA
66 vaccination may explain why mRNA vaccines have an increased efficacy compared to vector-based
67 formulations. Further investigation on these differences will be of particular interest for vaccine
68 development and efficacy, especially for the next-generation of vector-based vaccines.

69

70 **Keywords**

71 SARS-CoV-2, mRNA vs vector-based vaccination, variants of concern, protective immunity,
72 persistence of vaccination response

73

74 1. Introduction

75 In response to the global SARS-CoV-2 pandemic, multiple vaccines have been developed, tested and
76 licensed for use within record time (1-4). As vaccination coverage became more widespread at the
77 beginning of 2021, countries experienced a reduction in SARS-CoV-2 infections (5, 6), although case
78 numbers have again begun to increase in recent months due to spread among and by unvaccinated
79 individuals (7) as well as longevity-related reductions in vaccine protection (8-11). Although a
80 measurable correlate of protection that either prevents SARS-CoV-2 infection or limits COVID-19
81 disease progression is not yet defined, sufficient levels of neutralizing antibodies are assumed to be a
82 key element (12, 13). As in most other countries, the German national vaccination strategy (until June
83 7th 2021) was based on prioritization by occupation, underlying medical conditions or advanced age.
84 Currently, 56.8 million German residents are reported to be completely vaccinated (68.3% coverage),
85 with a further 2.4 million having so far received one dose. The majority of doses administered based on
86 delivery numbers in Germany are BNT162b2 from Pfizer (77.0%), followed by Astra Zeneca AZD1222
87 (11.3%), Moderna's mRNA-1273 (8.7%) and Janssen's single-shot Ad26.CoV2.S (3.0%;
88 impfdashboard.de and rki.de as of November 25th 2021). However, based on a lack of efficacy data from
89 phase III clinical trials, the German Standing Committee on Vaccination (STIKO) recommended
90 AZD1222 only for use in those below the age of 60. Following reports of moderate to severe
91 thrombocytopenia and atypical thrombosis cases after AZD1222 vaccination in spring 2021 (14-16),
92 temporary suspensions and eligibility restrictions were not only enacted in Germany (on March 15th
93 2021) but in 12 other EU member states (17). Administration of AZD1222 was resumed by the 1st of
94 April 2021 in Germany, however only for those above the age of 60 or after an individual risk analysis.
95 Individuals who had received a first dose of AZD1222 and were below the age of 60 were instead offered
96 a mRNA-based vaccine as second dose which resulted in a heterologous prime-boost vaccination
97 scheme (18). Although these "mix and match" approaches were not covered by the initial licensing
98 terms, it has by now been shown that they result in a more robust humoral and cell-mediated immune
99 response compared to the homologous AZD1222 immunisation (19, 20). While multiple studies have
100 so far investigated vaccine-induced responses, predominantly in at-risk groups such as dialysis or
101 transplant recipients (21, 22), groups with increased exposure risk such as health care workers (23-25)
102 or as part of the initial clinical efficacy trials which in general enrol healthier than average populations
103 (26), we report immunological vaccination response data from the general adult population. By using
104 samples from a population-based seroprevalence study (MuSPAD), which assessed SARS-CoV-2
105 seroprevalence from July 2020 to August 2021 in eight regions in Germany (27), we examined the
106 dynamics of vaccine-induced humoral responses using MULTICOV-AB (28) and an ACE2-RBD
107 competition assay (29) to analyse ACE2 binding inhibition.

108 2. Methods

109 2.1 MuSPAD study recruitment

110 Vaccination responses were analysed in participants of the Multi-local and serial cross-
111 sectional prevalence study on antibodies against SARS-CoV-2 in Germany (MuSPAD) study, a
112 nationwide population-based SARS-CoV-2 seroprevalence study (27) from July 2020 to August 2021.
113 The study was approved by the Ethics Committee of the Hannover Medical School (9086_BO_S_2020).
114 MuSPAD participants were recruited by age- and gender-stratified random sampling based on records
115 from the respective local residents' registration offices. Study locations in eight regions across Germany
116 were selected in spring 2020 based on differing epidemic activity at that time. In addition to the
117 successive cross-sectional study design, certain study locations were sampled longitudinally within a 3-
118 4 month interval. At the study centre, following written informed consent, all eligible participants (>18
119 years) were subject to a standardised computer-based interview using the digital health tool PIA

120 (Prospective Monitoring and Management-App) to gather basic sociodemographic data, information on
121 pre-existing medical conditions including a previously confirmed SARS-CoV-2 infection or a SARS-
122 CoV-2 vaccination, once it became available in Germany in late December 2020. Information about
123 SARS-CoV-2 infections or vaccinations are self-reported. After serum was obtained by venipuncture
124 from a serum gel S-Monovette (Sarstedt), samples were aliquoted in Matrix 2D Barcoded Screw Top
125 Tubes (Thermo Scientific) at the Institute of Transfusion Medicine and Immunohematology and frozen
126 at -20°C before being transported on dry ice to the Hannover Unified Biobank (Germany). After
127 registration and quality control, one serum aliquot was shipped to the Natural and Medical Sciences
128 Institute (Reutlingen, Germany) where they were stored at -80°C until analysis.

129 *2.2 Study design and eligibility*

130 Our study contains a total of 1821 samples from 1731 MuSPAD participants which were divided into
131 three subgroups to examine different aspects of the vaccine-induced humoral response. Based on our
132 inclusion criteria, individual samples can be part of several subgroups.

133 1. Individuals who received a homologous or heterologous full two-dose vaccination with AZD1222,
134 BNT162b2 and mRNA-1273 or the one-dose vaccine Ad26.CoV2.S with a blood sample taken at
135 least 7 days but no more than 65 days post the last vaccination (hereon referred to as “mix and match
136 sample cohort”)

137 2. Individuals who donated one blood sample following a two-dose homologous vaccination with
138 BNT162b2 or mRNA-1273 within the defined time frames of day 5 to 12, day 26 to 30, day 54 to
139 58, day 94 to 103, day 129 to 146 or day 176 to 203 after the second dose to monitor antibody kinetics
140 (hereon referred to as “time point sample cohort”)

141 3. Individuals with paired blood samples taken at two separate successive time points where the first
142 sample had to be taken a minimum of seven days after the second homologous dose of BNT162b2
143 (hereon referred to as “longitudinal sample cohort”).

144 All samples originated from the following locations where the MUSPAD study had previously been
145 scheduled to take place and were collected from January-August 2021: Aachen (Städteregion),
146 Magdeburg (Stadtkreis), Osnabrück (Stadt- und Landkreis), Chemnitz (Stadtkreis) or Landkreis
147 Vorpommern-Greifswald. A flow chart to illustrate sample selection from the entire MuSPAD cohort
148 can be found in **Fig. S1**. Basic sociodemographic information and details of comorbidities (hypertension,
149 cardiovascular disease, diabetes, lung disease, immunosuppression, cancer) for each group are provided
150 in more detail in **Table 1** and **Table S1**. Apart from the homologous BNT162b2 samples which are part
151 of our mix and match sample cohort, the maximum available sample number meeting the specified
152 criteria in groups 1-3 was used. For the homologous BNT162b2 vaccination samples within our mix and
153 match sample cohort, we applied a random selection from the entire available sample pool of BNT162b2
154 vaccinees who took part in the MuSPAD study to select 771 sera. Individuals with a previous SARS-
155 CoV-2 infection either defined by a positive SARS-CoV-2 PCR or antigen test result, or a nucleocapsid
156 IgG normalisation ratio above 1 are listed separately (hereon referred to as “recovered”) within the mix
157 and match sample cohort. Additional sample eligibility criteria were having a complete vaccination
158 record (manufacturer and vaccination dates) and information on age and gender as part of the
159 participant’s metadata.

160 *2.3 MULTICOV-AB*

161 Vaccine-induced humoral responses were analysed using MULTICOV-AB (28), a previously published
162 multiplex immunoassay that includes both antigens of SARS-CoV-2 (e.g. Spike, Receptor Binding
163 Domain (RBD), S1 domain, S2 domain and nucleocapsid) and the endemic coronaviruses (OC43,
164 HKU1, NL63 and 229E). Samples were processed using an automated platform on a Beckman Coulter
165 i7 pipetting robot as previously described (30). Briefly, samples were thawed at room temperature,

166 vortexed and then centrifuged at 2000 g for 3 mins to pellet any cell debris within the sample. Samples
167 were then opened using a LabElite DeCapper SL (Hamilton Company). Opened sample matrix racks
168 were then loaded into the pipetting robot, where the sample was diluted 1:200 in assay buffer, before
169 being combined in a 384-well plate and mixed 1:1 with 1x bead mix (see **Table S2** for antigen panel),
170 resulting in a final dilution of 1:400. Samples were then incubated in a Thermomixer (Eppendorf) for 2
171 h at 1400 rpm, 20°C, in darkness. Following this initial incubation, samples were washed to remove
172 unbound antibodies using an automated magnetic plate washer (Biotek). Bound IgG was detected by
173 adding R-phycoerythrin labelled goat-anti-human IgG (3 µg/mL; #109-116-098, Jackson
174 Immunoresearch Labs) and incubating for a further 45 mins at 1400 rpm, 20°C, in darkness. Following
175 a further washing step, beads were resuspended in 100 µl of wash buffer, shaken for 1 min at 1400 rpm
176 and then measured once on a FLEXMAP 3D instrument (Luminex Corporation) using the following
177 settings: Timeout 100 sec, Gate 7500-15000, Reporter Gain: Standard PMT, 40 events. 3 quality control
178 (QC) samples were included in octuplicate per plate. Any sample that failed QC was remeasured. Raw
179 median fluorescence intensity (MFI) values were normalised to a QC sample for all antigens as in (24,
180 31).

181 *2.4 ACE2-RBD competition assay*

182 To enable high-throughput screening of ACE2-RBD binding inhibition in the presence of sera, a
183 previously established ACE2-RBD competition assay (29) was automated on a Beckmann Coulter i7
184 pipetting robot. 1:20 previously diluted samples from MULTICOV-AB were diluted 1:200 in ACE2
185 buffer (29) containing 150 ng/mL biotinylated ACE2. Samples were then mixed 1:1 with 1x VoC
186 (Variant of Concern) bead mix containing RBDs of SARS-CoV-2 wild-type and the Alpha, Beta,
187 Gamma, Delta VoCs (**Table S3**), resulting in a final dilution of 1:400. Samples were then incubated in
188 a Thermomixer for 2 hours at 1400 rpm, 20°C, in darkness. Following this initial incubation, samples
189 were washed to remove unbound ACE2 using an automated magnetic plate washer. ACE2 was detected
190 using R-phycoerythrin labelled streptavidin (2 µg/mL, #SAPE-001, Moss) by incubating the bead-
191 sample mix for a further 45 mins at 1400 rpm, 20°C, in darkness. Following a further washing step,
192 beads were resuspended in 100 µl of wash buffer, shaken for 1 min at 1400 rpm and then measured once
193 on a FLEXMAP 3D instrument using the following settings: Timeout 100 sec, Gate 7500-15000,
194 Reporter Gain: Standard PMT, 40 events. As controls, 12 blank wells, 10 wells with 150 ng/mL ACE2
195 alone and 10 wells with an ACE2 QC sample were included. ACE2 binding inhibition was calculated
196 as percentage ACE2 inhibition as in (29) with 100% indicating maximum ACE2 binding inhibition and
197 0% no ACE2 binding inhibition. Samples with an ACE2 binding inhibition less than 20% are classified
198 as non-responders (29).

199 *2.5 Data analysis and statistics*

200 Initial results collation and matching to metadata was done in Excel 2016 and R 4.1.0 (32).
201 For pair-wise comparisons of titres and ACE2 binding inhibition between vaccination schemes within
202 our mix and max sample cohort, we used a two-sided Brunner-Munzel/generalised Wilcoxon test (33)
203 with a significance level of 0.05 as part of the lawstat package (34). In each comparison of two
204 vaccination schemes, the test assesses if a titre (or ACE2 binding inhibition) tends to larger (smaller)
205 values under one vaccination scheme in comparison to the other. Where indicated, we adjusted for
206 multiple testing by using Holm's procedure (33) to control the family-wise error rate to be below 0.05.
207 To investigate the impact of age, sex, comorbidities and time post-vaccination on the ACE2 binding
208 inhibition between the different vaccination schemes, we used a normal linear mixed model for logit-
209 transformed ACE2 binding inhibition. Negative measurement values were replaced by 0.001 to enable
210 the transformation. The model included additive effects of age, sex, time post-vaccination (peak
211 response period: 7-27 days vs plateau response period: 28-65 days) and comorbidities (cardiovascular
212 disease, hypertension, diabetes, lung disease and cancer/immunosuppression (which were combined to

213 a binary indicator based on low sample numbers). The model further included a random effect defined
214 by the variable “plate number” to account for dependencies due to the measurement procedure, and
215 allowed for heteroscedastic variances for younger (≤ 70) and older (> 70) ages and vaccination types.
216 REML estimation was implemented using the lme function (nlme library (35)). Statistical testing was
217 based on the asymptotic normality of the estimates. As part of a sensitivity analysis, we extended the
218 model with interaction terms between each confounder and the time post-vaccination, allowing for
219 possibly differing effects in the peak (7-27 days) and plateau (28-65 days) period after the last
220 vaccination. Since the effects of the considered covariates were allowed to differ between the
221 vaccination schemes, we analysed only four vaccination schemes (BNT162b2/BNT162b2, mRNA-
222 1273/mRNA-1273, AZD1222/BNT162b2, AZD1222/AZD1222) with a sufficient sample size in the
223 mix and match study cohort. Four individuals with BNT162b2/BNT162b2 vaccination with missing
224 comorbidity metadata were excluded from this analysis. The described statistical comparison of
225 vaccination schemes within the mix and max cohort was performed after the exclusion of recovered
226 individuals. To assess the impact of a previous SARS-CoV-2 infection on RBD antibody titres and wild-
227 type ACE2 binding inhibition among the different vaccination schemes, we also used a two-sided
228 Brunner-Munzel test.

229 To generate a heat map for comparing antigen-specific antibodies formation across different vaccination
230 schemes within the mix and max sample cohort, normalised antibody responses were initially scaled
231 using the function “z-score”, before being plotted as a heat map. To evaluate longitudinal changes in
232 antibody response and ACE2 binding inhibition within our longitudinal sample cohort, changes from
233 T1 to T2 were calculated using log2 fold change. Any increase in titre or binding is represented by a
234 positive value, while decreases in titre or binding are represented by negative values.

235 Data visualisation was done in RStudio (Version 1.2.5001 running R version 3.6.1). Additional packages
236 “gplots” (34) and “beeswarm” (35) were used for specific displays. Graphs were exported from RStudio
237 and further edited in Inkscape (Version 0.92.4) to generate final figures.

238 *2.6 Role of the funders*

239 This work was financially supported by the Initiative and Networking Fund of the Helmholtz
240 Association of German Research Centres (grant number SO-96), the EU Horizon 2020 research and
241 innovation program (grant agreement number 101003480 - CORESMA), intramural funds of the
242 Helmholtz Centre for Infection Research and the State Ministry of Baden-Württemberg for Economic
243 Affairs, Labour and Tourism (grant numbers FKZ 3-4332.62-NMI-67 and FKZ 3-4332.62-NMI-68).
244 The funders had no role in study design, data collection and analysis, decision to publish, or preparation
245 of the manuscript.

246 **3. Results**

247 First, we examined differences in humoral responses between individuals who received homologous or
248 heterologous immunisation schemes within our mix and match sample cohort where vaccine dose
249 distribution is similar to the German vaccine coverage. Using MULTICOV-AB, we compared
250 vaccination-induced antibody titres generated against the full-length Spike trimer, RBD, S1 and S2
251 domains and found that mRNA-based homologous vaccinations induced a greater Spike (median
252 normalised MFI mRNA-1273 13.78, BNT162b2 12.49, AZD1222 5.68, Ad26.CoV2.S 3.65) RBD
253 (median normalised MFI mRNA-1273 29.12, BNT162b2 24.89, AZD1222 9.61, Ad26.CoV2.S 5.25)
254 and S1 response (median normalised MFI mRNA-1273 195.9, BNT162b2 139.8, AZD1222 56.40,
255 Ad26.CoV2.S 10.14) than vector-based ones (**Fig. 1**). When comparing between the two vector-based
256 vaccinations, the two-dose immunisation with AZD1222 resulted in higher titres than the one-dose
257 Ad26.CoV2.S from Janssen. For mRNA vaccines, Moderna’s mRNA-1273 produced a significantly
258 higher response than Pfizer’s BNT162b2 (p-values < 0.001 , **Table S5**). Heterologous dose vaccination

259 schemes resulted in comparable titres (for Spike and RBD) as homologous mRNA-vaccinated regimens
260 among our study group independent of the origin of the second dose (Spike normalised MFI
261 AZD/mRNA-1273 13.59, AZD/BNT162b2 13.27, RBD normalised MFI AZD/mRNA-1273 28.17,
262 AZD/BNT162b2 25.93). Heterologous titres were in addition significantly higher than those after a
263 homologous AZD1222 two-dose immunisation (p-values <0.001, **Table S5**). In line with their lower
264 titres, serological non-responder rate (defined as a Signal to Cutoff ratio (S/CO) below 1 for either Spike
265 or RBD) was highest for vector-based homologous vaccination schemes (**Table 2**).

266 As multiplex-based serology tests such as MULTICOV-AB offer the unique opportunity for in-depth
267 profiling of polyclonal antibody reactivity towards multiple viral antigens, we then assessed differences
268 in antibody specificities between the different vaccines. Within the mix and match sample cohort, we
269 observed that mRNA-based SARS-CoV-2 vaccinations resulted in reduced S2-specific antibody titres
270 compared to vector-based ones (**Fig. 1**). To investigate this unequal antibody distribution further, we
271 initially scaled titres for each individual antigen (**Fig. 2**), and found that while Spike, RBD, S1 titres
272 were low for both AZD1222 and Ad26.CoV2.S, S2-specific titres were considerably higher than
273 expected. We then calculated proportional ratios between antigens (**Table 3**), confirming that
274 homologous mRNA vaccination resulted in significantly higher proportion of RBD- (mRNA-1273
275 14.01-fold, BNT162b2 18.63-fold, AZD1222 5.23-fold) and S1-targeted antibodies (mRNA-1273
276 97.21-fold, BNT162b2 110.10-fold, AZD1222 33.48-fold) compared to S2-targeted immunoglobulins.
277 This over-representation of S1-targeting antibodies following mRNA vaccination, was also present in
278 those who received a heterologous dose schedule (AZD1222-mRNA-1273 47.60-fold, AZD1222-
279 BNT162b2 65.06-fold).

280 Having determined that mRNA-vaccines produce a significantly higher proportion of RBD and S1
281 antibodies, we next investigated their ACE2 binding inhibition as these antigens are predominantly
282 responsible for antibody-mediated virus neutralization (12, 13). For this, we used a previously published
283 RBD-ACE2 competition assay (21, 29), which detects neutralizing antibody activity only and is
284 comparable to classical viral neutralization assays (9, 29). As expected, homologous mRNA vaccination
285 resulted in higher ACE2 binding inhibition than homologous vector-based vaccination (median ACE2
286 binding inhibition mRNA-1273 0.93, BNT162b2 0.80, AZD1222 0.39, Ad26.CoV2.S 0.03, **Fig. 3**).
287 Neutralizing antibodies generated following vaccination with Ad26.CoV2.S resulted in minimal ACE2
288 binding inhibition, with only 8.3% being classified as responders (29). As variants of concern now
289 comprise the majority of infections globally (36), we also assessed ACE2 binding inhibition against the
290 Alpha, Beta, Gamma and Delta SARS-CoV-2 VoC strains. ACE2 binding inhibition was most similar
291 to wild-type for the Alpha variant, followed by Delta whereas Beta and Gamma variants had the largest
292 reductions in ACE2 binding inhibition (**Fig. S2**).

293 Due to the range of responses recorded for each dose combination and likely differences in population
294 characteristics as a result of changing vaccine recommendations, we examined whether confounders
295 (sampling time post-vaccination (ΔT), age, gender or comorbidities) were instead responsible. To
296 analyse impact of ΔT , we separated samples into 7 to 27 days post-final dose to capture peak response
297 and 28 to 65 days post-final dose to capture plateau response (**Fig. 4**). While there was a reduction in
298 median response for samples from individuals collected within the plateau phase, the pattern between
299 the vaccines remained consistent. While increasing age did result in small reductions in ACE2 binding
300 inhibition (only significant for BNT162b2, $p < 0.001$), the vaccine dosing scheme received had a
301 substantially larger effect, with the eldest age group (>79) of homologous mRNA vaccine recipients still
302 having increased IgG titres and ACE2 inhibition capacities than the youngest (26 to 45) AZD1222
303 recipients (**Fig. 4**). Regression modelling for ACE2 binding inhibition against wild-type confirmed the
304 decrease of ACE2 binding inhibition with time post-vaccination for all vaccination types except
305 homologous AZD1222 (**Table S4A**). While age did not cause a significant decrease for homologous

306 AZD1222, this may have been due to the low number of samples at both ends of the age range within
307 our cohort. For mRNA-1273, while age did result in a significant decrease during the peak period
308 ($p=0.029$), this was not present within the plateau phase ($p=0.615$). For homologous BNT162b2
309 vaccination, male sex seemed to be associated with a decreased ACE2 binding inhibition, although the
310 same was not true for mRNA-1273. Similar patterns were observed for the ACE2 binding inhibition
311 against Alpha, Beta, Gamma and Delta VoCs (**Table S4B-E**). As we observed serological non-
312 responders within our mix and match study cohort, we systematically evaluated their distribution among
313 the different immunisation schemes (**Table 2**). Overall, vector-based homologous vaccination (2.78%)
314 resulted in a higher proportion of non-responders than homologous mRNA-based vaccination (0.89%).
315 Neither age nor gender was a determining factor in being a non-responder.

316 As our population-based cohort also contained individuals who had been previously infected and then
317 vaccinated, we examined what effect this had upon their vaccine-induced response. As previously
318 observed (37), recovered and then vaccinated individuals developed high levels of IgG with strong
319 ACE2 binding inhibition (**Fig. 5, Table S6**). This increase was particularly apparent for the vector-based
320 vaccinations where median RBD IgG titres (AZD1222 24.69, Ad26.CoV2.S 36.53, **Fig. S3**) and median
321 ACE2 binding inhibition (AZD1222 0.93, Ad26.CoV2.S 0.71, **Fig. 5**) were significantly higher than in
322 SARS-CoV-2 naïve vaccinated individuals (median RBD IgG AZD1222 9.61, Ad26.CoV2.S 5.25, **Fig.**
323 **1**) and median ACE2 binding inhibition (AZD1222 39%, Ad26.CoV2.S 0.03%, **Fig. 3**).

324 Having determined that mRNA-based vaccination resulted in an increased humoral response, we
325 evaluated lifespan and antibody response kinetics using our time point sample cohort which were
326 selected to mimic key response periods for antibody-producing B-cell activity such as expansion, peak
327 and plateau phase after a complete vaccination scheme. Vaccine-induced titres and ACE2 binding
328 inhibition both initially increased, peaked during the second time point (26 to 30 days post-second dose),
329 and then decreased linearly as time increased (**Fig. 6**). ACE2 binding inhibition followed the same
330 pattern of decrease as time increased. In contrast to antibody levels, the percentage of non-responders
331 showed however a trend for increased decline already from time point 94 to 103 days post-second
332 vaccination onwards for BNT162b2, with 22.22% of samples considered as non-responders at 176-203
333 days post-second vaccination (**Table 2**). As already observed in Figure 1, mRNA-1273 (blue line)
334 resulted in higher titres and ACE2 binding inhibition compared to BNT162b2 (yellow line) for all
335 monitored time points. To validate this pattern of decreasing antibody titres and ACE2 inhibition
336 activity, we examined samples from a cohort of longitudinal donors (longitudinal sample cohort). Unlike
337 the time point sample cohort, this cohort contained paired samples from each donor which allows to
338 directly compare changes in titre and activity from the first sampling to the second sampling. While
339 these samples had a variable initial ΔT post-full vaccination (7-63 days), the sampling intervals between
340 first and second donation were more comparable (114-163 days). Overall, titres decreased (median RBD
341 68%) between their first and second sampling (**Fig. 7**). Among the different SARS-CoV-2 antigens,
342 RBD and S1 antibodies had the largest decrease, while Spike Trimer and S2 had the smallest. This
343 reduction in titre was reflected in ACE2 binding inhibition which also reduced substantially from the
344 first to second sampling (median 32%). ACE2 binding inhibition was also clearly decreased for all VoC
345 RBDs (Alpha 36%, Beta 30%, Gamma 29%, Delta 38%).

346 4. Discussion

347 We report both significant and substantial differences in humoral responses generated by the different
348 vaccines and dose regimens currently available in Germany, with homologous mRNA or combined
349 heterologous vector and mRNA vaccination approaches inducing significantly higher titres and ACE2
350 binding inhibition compared to homologous vector-based vaccination schemes. This expands on results
351 from on-going randomised and observational trials such as the ComCoV (38) or CoCo (39) study which
352 provided only information on AZD1222-BNT162b2 schemes (19, 40). Among homologous mRNA

353 regimens, we identified like others, that mRNA-1273 resulted in higher antibody titres and ACE2
354 binding inhibition than BNT162b2 (37, 41). While we have used an ACE2-RBD competition assay to
355 measure ACE2 binding inhibition as opposed to classic virus neutralization assays, this assay analyses
356 neutralizing antibodies as seen by its similar performance to VNT (9, 29). ACE2 inhibition assays
357 instead of a VNT have also already been used successfully by other groups to determine neutralizing
358 antibody activity (42). Methodically, MULTICOV-AB and the ACE2-RBD competition assay are also
359 complementary and are measured using a single initial sample dilution which further reduces variability
360 between their results. As expected, titres and ACE2 binding inhibition for AZD1222 were reduced
361 compared to mRNA-based vaccination (40). By multiplex-based antibody profiling, we were able to
362 investigate these differences and determine that vector and mRNA-based vaccines induced a distinct
363 pattern of Spike subdomain-targeted antibodies. While vector-based formulations result in a
364 significantly larger proportion of S2-domain antibodies, RBD- and S1-domain antibodies dominated in
365 mRNA vaccines. While these observations require further detailed investigation, the relative over-
366 representation of RBD- and S1-targeting antibodies within mRNA vaccines is particularly intriguing as
367 these two antigens comprise the majority of neutralizing antibody activity (13). Despite the lack of a
368 clearly defined correlation of vaccine efficacy and neutralizing antibody levels, it appears logical that
369 increased antibody levels specific to virus protein-mediating cell attachment could result in enhanced
370 levels of protection from infection and contribute to observed differences in levels of vaccine efficacy
371 and effectiveness (2, 43, 44). Interestingly, a series of modelling studies have now linked levels of
372 neutralizing antibodies to vaccine efficacy (12, 45).

373 An additional finding of our study requiring further investigation is the relatively poor performance of
374 Ad26.CoV2.S, particularly for induction of neutralizing antibodies for both SARS-CoV-2 wild-type and
375 VoC RBDs. While some studies have reported sufficient levels of neutralizing activity after vaccination
376 with Ad26.CoV2.S (4), others identified minimal neutralizing activity, particularly when compared to
377 other COVID-19 vaccines from Pfizer or Moderna (41). The relatively poor performance of
378 Ad26.CoV2.S in inducing an antibody response has also been identified by researchers studying other
379 bodily fluids (e.g. breast milk), who found that Ad26.CoV2.S produced significantly fewer IgA
380 antibodies than BNT162b2 or mRNA-1273 (46). While our Ad26.CoV2.S sample group size is low
381 (n=29), it is three times larger than a recent study from the manufacturer which reported neutralizing
382 activity against Delta and other VoCs (n=8, (47)). It should be noted that four of the eight individuals
383 within their cohort were reported as being spike seropositive at baseline which is a consistent finding
384 with our cohort, where strong ACE2 binding inhibition was only achieved in those individuals who had
385 been previously infected. Our median time point is however earlier than the reported peak of antibody
386 activity (4, 48). Further independent investigations into the neutralizing activity generated by single-
387 dose of Ad26.CoV2.S to clarify those differing results within SARS-CoV-2 naïve individuals are
388 therefore urgently needed.

389 Among confounding variables, we identified like others that age resulted in a general reduction in titre
390 and ACE2 binding inhibition (10, 37, 49), although the vaccine dose scheme received had a more
391 significant effect. While recovered individuals developing high titres and ACE2 binding inhibition once
392 vaccinated has been previously reported (37, 40), we found that these responses were similar among all
393 vaccines and dose schedules. Given that current German guidelines require a six month post-positive
394 PCR waiting period before receiving a first dose, this suggests that such individuals would be suitable
395 for all currently licensed vaccines, assuming they meet pre-existing EMA and STIKO criteria. This
396 ability to use all vaccines and generate a substantial response will be of particular public health
397 importance, given the on-going booster dose administration which could impact availability for some
398 vaccine brands, as happened earlier in 2021.

399 Our results on the longevity of the humoral response post-vaccination is similar to others, in identifying
400 an initial peak from approximately 28 days post-second dose onwards followed by a gradual reduction
401 over time (50). As expected, ACE2 binding inhibition and titre are mostly mirrored in their decline over
402 time. However, the increased numbers of non-responders from BNT162b2-vaccinated individuals from
403 six months after the second vaccine needs further careful monitoring until a precise correlate of
404 protection has been defined. Among the different SARS-CoV-2 antibodies, it is unsurprising that the
405 RBD and S1 underwent the greatest reductions as they had the largest titres to begin with. Between
406 VoCs, we did not identify any apparent differences in ACE2 binding inhibition within the differing
407 vaccines and dose regimens for confounders. Instead, again vaccine or dose regimen received had the
408 largest effect upon ACE2 binding inhibition. The VoCs themselves followed a previously published
409 pattern (9, 21, 51), with the lowest reduction for the Alpha variant, and the highest for the Beta and
410 Gamma variants. It should be stated that we in our analysis of longitudinal samples, there is a wide
411 variety of timeframes post-vaccination, meaning that initial samples are collected both before, during
412 and after the initial peak response at 28 days. While we have then made the assumption that decreases
413 in responses would be linear to the second sampling, this is not the case as some of the early collected
414 samples (e.g. 7 days post-second vaccination) would have initially increased before later decreasing.
415 However, our purpose of this analysis was to measure changes over a larger timeframe (4 months) and
416 the difference in time from first to second sampling, means that all samples should be in the decline
417 phase by their second sampling.

418 Our manuscript has several limitations, namely that we are only measuring antibodies (including
419 neutralizing antibodies) that are present within serum. As previously stated, we have used an ACE2-
420 RBD competition assay to measure inhibition of ACE2 binding instead of classical virus neutralization
421 assays, although the results of this assay have already been shown to be similar to VNT and are known
422 to be specific to neutralizing antibody responses only. While neutralizing antibodies themselves are
423 considered a strong correlate for protection (13), other components that are not measured within our
424 assays such as T-cell mediated immunity will also offer protection (52, 53). Our use of serum also means
425 that memory B-cells, which are involved in protection against severe disease progression (54), are
426 equally excluded from our analysis. Our study cohort consists of relatively low sample numbers for both
427 heterologous and Ad26.CoV2.S vaccinations whereas BNT162b2 samples are overrepresented.
428 However, our sample numbers are similar or in the case of Ad26.CoV2.S exceed other previously
429 published work making our study one of the largest independent evaluation studies of this vaccine. Our
430 BNT162b2 sample size mimics dose distribution in Germany where approximately 70% of delivered
431 vaccine doses were from Pfizer. Our study population is also relatively similar in regard to age and
432 gender.

433 Overall, we provide data on the vaccine-induced humoral response for all currently available mRNA-,
434 vector-based and heterologous immunisation regimens in Germany. Within our population-based
435 cohort, mRNA homologous or heterologous vaccination resulted in increased humoral responses. Our
436 multiplex approach identified differences in quantities and ratios of RBD- and S1-targeting antibodies
437 following mRNA homologous or heterologous vaccination. Further investigation into this targeting will
438 be of particular interest to improve vaccine performance particularly for next generation vector-based
439 vaccines.

440 **Contributors**

441 MS, AD, BL, GK and NSM conceived the study. NSM, MS, BL, VM, SC, and GK procured funding.
442 AD, MS, MB and NSM, designed the experiments. AD, JG, JJ, and DJ performed the experiments. AD,
443 MS, MB, MH, JO, SC, NW, SG, JH and BK performed data collection and analysis. AD, MB, MH, BK
444 generated figures and tables. TT, KF, TI and NK organized sample collection and processing. AD, MS,
445 MH and BK verified the underlying data. AD, MS and MB wrote the manuscript. AD, MH, JO, PH, BL,

446 NSM, MS, YK, DG, VM, DJ, PDK, BT, UR, TT, KF, NK, TI, TK, AR, CS, AR, AM, NG and
447 contributed resources or were involved in project administration. All authors critically reviewed and
448 approved the final manuscript.

449 **Declaration of Interest**

450 NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute
451 at the University of Tübingen is involved in applied research projects as a fee for services with the
452 Luminex Corporation. The other authors declare no competing interest.

453 **Acknowledgments**

454 First and foremost, we would like to thank the MuSPAD participants for their willingness and
455 commitment to make this study possible. We also want to thank all laboratory members and
456 administrative staff at the Institute of Transfusion Medicine and Immunohematology in Plauen for
457 continued excellent technical and organizational support in sample processing. We are grateful to the
458 entire team of BOS112 for running of MuSPAD study sites. We sincerely thank all participating
459 counties, cities and local health care authorities for their support. We thank Astrid Hans and Carina
460 Lützwow for administrative assistance. We thank members of the Multiplex Immunoassays Group at the
461 NMI for their assistance in sample arrival and storage.

462 **Data Sharing Statement**

463 Data is available upon request from the corresponding authors.

464 **Competing interests**

465 The other authors declare no competing interests.

466 **References**

- 467 1. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy
468 of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
469 randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet*. 2021;397(10269):99-111.
- 470 2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the
471 mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384(5):403-16.
- 472 3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of
473 the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*. 2020;383(27):2603-15.
- 474 4. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and
475 Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *New England Journal of Medicine*.
476 2021;384(23):2187-201.
- 477 5. RKI. COVID-19 Dashboard
478 https://experience.arcgis.com/experience/478220a4c454480e823b17327b2bf1d4/page/page_1/2021
479 [1](#) [
- 480 6. Corona.stat.uni-muenchen.de/maps/. <https://corona.stat.uni-muenchen.de/maps/2021> [
- 481 7. Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring
482 Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S.
483 Jurisdictions, April 4-July 17, 2021. *MMWR Morbidity and mortality weekly report*. 2021;70(37):1284-
484 90.
- 485 8. Government I. Verified results after receiving the vaccine among the first vaccinated group.
486 In: Committee VEaSFU, editor. https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf2021.
- 487

- 488 9. Dulovic A, Strengert M, Ramos GM, Becker M, Griesbaum J, Junker D, et al. Diminishing
489 immune responses against variants of concern in dialysis patients four months after SARS-CoV-2
490 mRNA vaccination. medRxiv. 2021:2021.08.16.21262115.
- 491 10. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody
492 response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet
493 Regional Health – Europe.
- 494 11. Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al. Evidence for increased
495 breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
496 Nature Medicine. 2021;27(8):1379-84.
- 497 12. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence
498 for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-8.
- 499 13. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
500 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
501 Nature Medicine. 2021;27(7):1205-11.
- 502 14. Althaus K, Möller P, Uzun G, Singh A, Beck A, Bettag M, et al. Antibody-mediated
503 procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia.
504 Haematologica. 2021;106(8):2170-9.
- 505 15. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
506 Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine.
507 2021;384(22):2092-101.
- 508 16. Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous
509 thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca
510 ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.
- 511 17. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after
512 reports of blood clots. BMJ. 2021;372:n699.
- 513 18. Vygen-Bonnet S, Koch J, Bogdan C, Harder T, Heininger U, Kling K, et al. Beschluss der STIKO
514 zur 5. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche
515 Begründung. 2021(19):24-36.
- 516 19. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et
517 al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1
518 nCoV-19/BNT162b2 vaccination. Nature Medicine. 2021;27(9):1525-9.
- 519 20. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and
520 reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nature Medicine.
521 2021;27(9):1530-5.
- 522 21. Strengert M, Becker M, Ramos GM, Dulovic A, Gruber J, Juengling J, et al. Cellular and
523 humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. EBioMedicine.
524 2021;70.
- 525 22. Carr EJ, Wu M, Harvey R, Wall EC, Kelly G, Hussain S, et al. Neutralising antibodies after
526 COVID-19 vaccination in UK haemodialysis patients. The Lancet. 2021;398(10305):1038-41.
- 527 23. Harsch IA, Ortloff A, Reinhöfer M, Epstude J. Symptoms, antibody levels and vaccination
528 attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers. GMS
529 hygiene and infection control. 2021;16:Doc15.
- 530 24. Becker M, Dulovic A, Junker D, Ruetalo N, Kaiser PD, Pinilla YT, et al. Immune response to
531 SARS-CoV-2 variants of concern in vaccinated individuals. Nature Communications. 2021;12(1):3109.
- 532 25. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies
533 and associated factors in healthcare workers: a systematic review and meta-analysis. The Journal of
534 hospital infection. 2021;108:120-34.
- 535 26. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine
536 effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews
537 Immunology. 2021;21(10):626-36.
- 538 27. Gornyk D, Harries M, Glöckner S, Strengert M, Kerrinnes T, Heise J-K, et al. SARS-CoV-2
539 seroprevalence in Germany. Dtsch Arztebl International. 2021;0(OnlineFirst):1-.


- 540 28. Becker M, Strengert M, Junker D, Kaiser PD, Kerrinnes T, Traenkle B, et al. Exploring beyond
541 clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-
542 reactivity. *Nature Communications*. 2021;12(1):1152.
- 543 29. Junker D, Dulovic A, Becker M, Wagner TR, Kaiser PD, Traenkle B, et al. Reduced serum
544 neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay.
545 medRxiv. 2021:2021.08.20.21262328.
- 546 30. Renk H, Dulovic A, Becker M, Fabricius D, Zernickel M, Junker D, et al. Typically asymptomatic
547 but with robust antibody formation: Children's unique humoral immune response to SARS-CoV-2.
548 medRxiv. 2021:2021.07.20.21260863.
- 549 31. Planatscher H, Rimmele S, Michel G, Potz O, Joos T, Schneiderhan-Marra N. Systematic
550 reference sample generation for multiplexed serological assays. *Sci Rep*. 2013;3.
- 551 32. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R
552 Foundation for Statistical Computing; 2021.
- 553 33. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. *Scandinavian Journal of*
554 *Statistics*. 1979;6(2):65-70.
- 555 34. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. *gplots: Various R*
556 *Programming Tools for Plotting Data*. 3.1.1 ed2021.
- 557 35. Eklund A, Trimble J. *beeswarm: The Bee Swarm Plot, an Alternative to Stripchart*. 0.4.0
558 ed2021.
- 559 36. CoVariants. Shared Mutations (<https://covariants.org/shared-mutations>) [
560 37. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 Antibody
561 Response Following Vaccination With BNT162b2 and mRNA-1273. *JAMA*. 2021.
- 562 38. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
563 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral
564 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
565 *Lancet*. 2021;398(10303):856-69.
- 566 39. Behrens GMN, Cossmann A, Stankov MV, Schulte B, Streeck H, Förster R, et al. Strategic Anti-
567 SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in
568 Healthcare Professionals. *Infectious Diseases and Therapy*. 2020;9(4):837-49.
- 569 40. Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A, et al. Quantitative SARS-CoV-2 anti-
570 spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
571 *Clin Microbiol Infect*. 2021;27(10):1516.e7-.e14.
- 572 41. Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Mulligan MJ, et al. Comparison of
573 Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2
574 Variants. *bioRxiv*. 2021:2021.07.19.452771.
- 575 42. Lopez E, Haycroft ER, Adair A, Mordant FL, O'Neill MT, Pymm P, et al. Simultaneous
576 evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. *JCI Insight*. 2021;6(16).
- 577 43. ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. *New England Journal of*
578 *Medicine*. 2021;385(6):571-2.
- 579 44. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative
580 Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing
581 COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States,
582 March-August 2021. *MMWR Morbidity and mortality weekly report*. 2021;70(38):1337-43.
- 583 45. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against
584 symptomatic and asymptomatic SARS-CoV-2 infection. *Nature Medicine*. 2021.
- 585 46. Fox A, DeCarlo C, Yang X, Norris C, Powell RL. Comparative profiles of SARS-CoV-2 Spike-
586 specific milk antibodies elicited by COVID-19 vaccines currently authorized in the USA. *medRxiv*.
587 2021:2021.07.19.21260794.
- 588 47. Jongeneelen M, Kaszas K, Veldman D, Huizingh J, van der Vlugt R, Schouten T, et al.
589 Ad26.COVS.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern.
590 *bioRxiv*. 2021:2021.07.01.450707.

- 591 48. Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, et al. Durable Humoral and
592 Cellular Immune Responses 8 Months after Ad26.COVS Vaccination. *New England Journal of*
593 *Medicine*. 2021;385(10):951-3.
- 594 49. Shrotri M, Fragaszy E, Geismar C, Nguyen V, Beale S, Braithwaite I, et al. Spike-antibody
595 responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch
596 study). *medRxiv*. 2021:2021.05.12.21257102.
- 597 50. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al. Antibody
598 Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *New*
599 *England Journal of Medicine*. 2021;384(23):2259-61.
- 600 51. van Gils MJ, Lavell AHA, van der Straten K, Appelman B, Bontjer I, Poniman M, et al. Four
601 SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants.
602 *medRxiv*. 2021:2021.09.27.21264163.
- 603 52. Mateus J, Dan Jennifer M, Zhang Z, Rydyznski Moderbacher C, Lammers M, Goodwin B, et al.
604 Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T
605 cells. *Science*.0(0):eabj9853.
- 606 53. Israelow B, Mao T, Klein J, Song E, Menasche B, Omer Saad B, et al. Adaptive immune
607 determinants of viral clearance and protection in mouse models of SARS-CoV-2. *Science*
608 *Immunology*.0(0):eabl4509.
- 609 54. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct
610 antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following
611 mRNA vaccination. *Sci Immunol*. 2021;6(58).

612

613


614 **Figures**
615



616
617
618
619
620
621
622
623
624
625
626
627
628

Fig. 1. Different SARS-CoV-2 vaccination schemes result in distinct humoral responses.

IgG antibody titres against full-length Spike trimer (a), receptor-binding domain (RBD) (b), S1 domain (c) and S2 domain (d) were measured with MULTICOV-AB. Individuals received either homologous mRNA-1273 (M/M, blue, n=272), BNT162b2 (P/P, orange, n=738) or AZD1222 (A/A, green, n=228), heterologous AZD1222-mRNA-1273 (A/M, light blue, n=24), AZD1222-BNT162b2 (A/P, light green, n=114), or a single dose of Ad26.CoV2.S (J, grey, n=24). Raw MFI values were normalised against QC samples to generate signal ratios for each antigen. Data is shown as box and whisker plots overlaid with strip charts. Boxes represent medians, 25th and 75th percentiles and whiskers show the largest and smallest non-outlier values based on 1.5 IQR calculation. Time between sampling and full vaccination is displayed as mean and SD for each group. Number of samples per vaccination scheme are stated below.




630 **Fig. 2. Humoral immune response after mRNA vaccination is skewed towards increased RBD and S1 titres,**
631 **while vector-based vaccination results in increased S2 antibody levels.**

632 Antigen-specific antibody titres measured in the mix and match sample cohort were scaled and centred per antigen.
633 Resulting values greater than 2.5 and smaller than -2.5 were set to these extreme values instead. Samples were
634 then clustered within their subgroups based on immunisation scheme and are displayed as a heat map. Negative
635 values represent below average titres and positive values represent positive above average titres per antigen. Colour
636 shades indicate low (grey) to high (red) value distribution. A/A – two-dose AZD1222. A/M – first dose AZD1222,
637 second dose mRNA-1273. A/P – first dose AZD1222, second dose BNT162b2. M/M – two-dose mRNA-1273.
638 P/P – two-dose BNT162b2. J – one-dose Ad26.CoV2.S.

639

640




641

642 **Fig. 3. Different vaccination schemes impact ACE2 binding inhibition against SARS-CoV-2 wild-type.**

643 ACE2 binding inhibition against the SARS-CoV-2 wild-type (B1 isolate) RBD was assessed by an ACE2-RBD
644 competition assay for homologous mRNA (mRNA-1273 (M/M, blue), BNT162b2 (P/P, orange)), heterologous
645 prime-boost (AZD1222-mRNA-1273 (A/M, light blue), AZD1222-BNT162b2 (A/P, light green) or vector-based
646 (AZD1222-AZD1222 (A/A, green), Ad26.CoV2.S (J, grey)) vaccination schemes in the mix and match cohort.
647 Data is shown as box and whisker plots overlaid with strip charts. Boxes represent medians, 25th and 75th
648 percentiles and whiskers show the largest and smallest non-outlier values based on 1.5 IQR calculation. The
649 threshold for non-responsive samples (ACE2 binding inhibition less than 20%) is shown as dotted line. All samples
650 below this threshold can be considered non-responsive. Time between sampling and full vaccination is displayed
651 as mean and SD for each group. Number of samples per vaccination scheme are stated below. ACE2 binding
652 inhibition towards VoCs can be found in Fig. S2.

653




654

655

656 **Fig. 4. Effect of time post-vaccination, gender and age on ACE2 binding inhibition for different SARS-CoV-**
 657 **2 vaccination schemes.**


658 ACE2 binding inhibition against the SARS-CoV-2 wild-type (B1 isolate) RBD was assessed by an ACE2-RBD
 659 competition assay. Samples were split according to vaccination scheme (homologous mRNA (mRNA-1273 (M/M,
 660 BNT162b2 (P/P, orange)), heterologous prime-boost (AZD1222-mRNA-1273 (A/M, light blue), AZD1222-
 661 BNT162b2 (A/P, light green) or vector-based (AZD1222-AZD1222 (A/A, green), Ad26.CoV2.S (J, grey)). To
 662 display impact of potential confounders, samples were further split in time post-vaccination up to 27 and above 27
 663 days (a), gender (b) and indicated age groups (c). Boxes represent medians, 25th and 75th percentiles and whiskers
 664 show the largest and smallest non-outlier values based on 1.5 IQR calculation. The threshold for non-responsive
 665 samples (ACE2 binding inhibition less than 20%) is shown as dotted line. All samples below this threshold can be
 666 considered non-responsive. Time between sampling and full vaccination is displayed as mean and SD for each
 667 group. Number of samples per vaccination scheme are stated below the figure. Statistical significance was
 668 calculated by a regression model (Table S4).
 669



670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688

Fig. 5. SARS-CoV-2 vaccination boosts ACE2 binding inhibition among recovered individuals independent of vaccination scheme


Differences in vaccination responses of recovered previously SARS-CoV-2 infected individuals from our mix and match cohort were analysed using an ACE2-RBD competition assay (a). SARS-CoV-2 infection status was based on a previous self-reported positive PCR/antigen test or a MULTICOV-AB nucleocapsid IgG normalisation ratio above 1. Samples were split according to vaccination scheme (homologous mRNA (mRNA-1273 (M/M, blue), BNT162b2 (P/P, orange)), heterologous prime-boost (AZD1222-mRNA-1273 (A/M, light blue), AZD1222-BNT162b2 (A/P, light green) or vector-based (AZD1222-AZD1222 (A/A, green), AdCoV2S (J, grey)). For clarity and comparison, ACE2 inhibition of SARS-CoV-2 naïve individuals are displayed (b). Boxes represent medians, 25th and 75th percentiles and whiskers show the largest and smallest non-outlier values based on 1.5 IQR calculation. If not enough sample to generate a box were present (minimum 5), then only the median is indicated by a line. The threshold for non-responsive samples (ACE2 binding inhibition less than 20%) is shown as dotted line. All samples below this can be considered non-responsive. Time between sampling and full vaccination is displayed as mean and SD for each group. Number of samples per vaccination scheme are stated below the figure. Results of a formal statistical comparison of recovered-vaccinated and SARS-CoV-2 naïve-vaccinated individuals are shown in Table S6.



689

690 **Fig. 6. Antibody and neutralization response kinetic up to 7 months after SARS-CoV-2 mRNA-vaccination**
691 Humoral vaccine response was assessed by MULTICOV-AB (a) and an ACE2-RBD competition assay (b) using
692 the time point sample set. Samples were either 5 to 12, 26 to 30, 54 to 58, 94 to 103, 129 to 146 and 176 to 203
693 days post-second dose of either a two-dose BNT162b2 (yellow, n=515) or mRNA-1273 (blue, n=82) vaccination.
694 Coloured line connects median response per time point and vaccine. Data is displayed as normalised IgG RBD
695 ratio or as ACE2 binding inhibition % where 100% indicates maximum binding inhibition and 0% no binding
696 inhibition. The threshold for non-responsive samples (ACE2 binding inhibition less than 20%) is shown as dotted
697 line. All samples below this threshold can be considered non-responsive.

698



699

700

701 **Fig. 7. Longitudinal mRNA vaccine response monitoring defines decreases over time**

702 Humoral response was assessed by MULTICOV-AB (a, b) and an ACE2-RBD competition assay (c, d) for all
 703 samples of the longitudinal sample set at indicated time points post-second dose of a complete BNT162b2
 704 vaccination scheme (n=90). Line graph illustrates longitudinal development of RBD-specific antibody levels (a)
 705 or ACE2 binding inhibition (c) towards WT RBD as time post-vaccination increases. The threshold (less than 20%
 706 ACE2 binding inhibition) for non-responsive samples within the ACE2-RBD competition assay is shown (dotted
 707 line). All samples below this threshold are considered non-responsive. SARS-CoV-2 antigen-specific differences
 708 in longitudinal humoral response are expressed as log₂ fold changes (b). Reduction in ACE2 binding inhibition
 709 for RBD of Alpha, Beta, Gamma and Delta VoC between sampling times is shown as difference (d).

710

711

712 **Table 1.** Demographics of study population (n. a.: not applicable; NA: not available).
713

Sample cohort (n)	SARS-CoV-2 infection status* (n)	ΔT in days post-vaccination	Vaccine (n)	Age (y), median (IQR)	Female (n, %)	Comorbidities (min. 1 / person) (n, %)	Number of comorbidities (mean, SD)		
Mix and match (1470)	+ (70)	7-65	M/M (13)	59 (11)	8 (61.54)	5 (38.46)	0.54 (0.84)		
			P/P (33)	66 (29)	25 (75.76)	13 (39.40)	0.61 (0.89)		
			A/A (12)	69 (7.25)	7 (58.33)	10 (83.34)	1.33 (0.85)		
			A/M (1)**	Age group 66-79	0 (0)	1 (100)	1 (0)		
			A/P (6)	56.5 (24.5)	3 (50.0)	4 (66.67)	0.83 (0.69)		
			J (5)	40 (15)	3 (60.0)	3 (60.0)	0.60 (0.49)		
	- (1400)	7-65	M/M (272)	56 (26)	162 (59.56)	108 (39.71)	0.55 (0.80)		
			P/P (738)	59 (26)	456 (61.79)	438 (46.05) 4 NA	0.74 (0.99)		
			A/A (228)	66 (10)	122 (53.51)	114 (50.0)	0.72 (0.87)		
			A/M (24)	68 (5)	15 (62.50)	14 (58.33)	0.79 (0.76)		
			A/P (114)	58.5 (20)	64 (56.14)	55 (48.25)	0.78 (1.02)		
			J (24)	61.5 (13.5)	15 (62.50)	11 (45.83)	0.75 (1.16)		
			Time points (597)	-	5-12	P/P (107)	64 (26)	57 (53.27)	61 (57.01)
M/M (40)	57.5 (26.75)	20 (50.0)				15 (37.50)	0.53 (0.81)		
26-30	P/P (103)	52 (41.5)			60 (58.25)	42 (41.18) 1 NA	0.76 (1.10)		
	M/M (8)	67 (39)			5 (62.50)	3 (37.50)	0.50 (0.71)		
54-58	P/P (92)	60.5 (19.5)			60 (65.22)	45 (48.91)	0.78 (0.95)		
	M/M (22)	56.5 (14.75)			17 (77.27)	5 (22.73)	0.32 (0.63)		
94-103	P/P (139)	60 (21.5)			87 (62.59)	72 (51.80)	0.83 (0.99)		
	M/M (7)	64 (8)			5 (71.43)	3 (42.86)	0.86 (1.12)		
129-146	P/P (38)	80 (23.5)			25 (68.79)	24 (63.16)	1.18 (1.19)		
	M/M (5)	83 (4)			2 (40.0)	3 (60.0)	1.20 (1.17)		
176-203	P/P (36)	50 (12.75)			30 (83.33)	11 (30.56)	0.36 (0.58)		
	M/M (0)	n. a.			n. a.	n. a.	n. a.		
Longitudinal (90)	-	1 st sample: 7-63			P/P (90)	58.0 (33.75)	65 (72.22)	45 (2 NA; 51.14)	0.8 (0.98)
		2 nd sample: 121-203				58.0 (33.0)	65 (72.22)	48 (53.33)	0.73 (0.95)

714 Different vaccines and combinations are abbreviated as follows: M/M (two-dose mRNA-1273), P/P (two-dose
715 BNT162b2), A/A (two-dose AZD1222), A/M (first dose AZD1222, second dose mRNA-1273), A/P (first dose
716 AZD1222, second dose BNT162b2) and J (one-dose Ad26.CoV2.S). The time points sample cohort contains only
717 homologous BNT162b2 and mRNA-1273 samples. The longitudinal sample cohort contains only homologous
718 BNT162b2.

719 * based on self-reported positive PCR/antigen test result at study centre visit and/or MULTICOV-AB nucleocapsid
720 IgG S/CO ratio above 1; ** only age group reported as n=1

721 **Table 2.** Vaccine non-responder rates across study population.

Sample cohort (n)	ΔT post-vaccination (days)	Vaccine (n)	Non-responders MULTICOV-AB (n, %)	Non-responders ACE2-RBD WT (n, %)	
Mix and match (1400)	7-65	M/M (272)	0 (0)	0 (0)	
		P/P (738)	9 (1.22)	18 (2.44)	
		A/A (228)	4 (1.75)	26 (11.40)	
		A/M (24)	0 (0)	0 (0)	
		A/P (114)	0 (0)	0 (0)	
		J (24)	3 (12.50)	22 (91.67)	
Time points (597)	5-12	P/P (107)	6 (5.61)	13 (12.15)	
		M/M (40)	1 (2.50)	1 (2.50)	
	26-30	P/P (103)	1 (0.97)	2 (1.94)	
		M/M (8)	0 (0)	0 (0)	
	54-58	P/P (92)	1 (1.09)	3 (3.26)	
		M/M (22)	0 (0)	0 (0)	
	94-103	P/P (139)	2 (1.44)	8 (5.76)	
		M/M (7)	0 (0)	0 (0)	
	129-146	P/P (38)	3 (7.89)	2 (5.26)	
		M/M (5)	1 (20.0)	1 (20.0)	
	176-203	P/P (36)	0 (0)	8 (22.22)	
		M/M (0)	n. a.	n. a.	
	Longitudinal (90)	1 st sample: 7-63	P/P (90)	2 (2.22)	3 (3.33)
		2 nd sample: 121-203		2 (2.22)	17 (18.89)

722 MULTICOV-AB non-responders were determined as in (28), with samples that had a signal to cut-off ratio below
723 1 for either the Spike or RBD being considered non-responders. ACE2-RBD non-responders were determined as
724 in (29), with samples that had a ACE2 binding inhibition less than 20% being considered non-responders. Different
725 vaccines and combinations are abbreviated as follows: M/M (two-dose mRNA-1273), P/P (two-dose BNT162b2),
726 A/A (two-dose AZD1222), A/M (first dose AZD1222, second dose mRNA-1273), A/P (first dose AZD1222,
727 second dose BNT162b2) and J (one-dose Ad26.CoV2.S). The time points sample cohort contains only homologous
728 BNT162b2 and mRNA-1273 samples. The longitudinal sample cohort contains only homologous BNT162b2.

729

730 **Table 3.** Antigen-specific ratios for different vaccination schemes.

Vaccine	Antibody target (95% CI)					
	RBD vs S	S1 vs S	S1 vs RBD	S vs S2	RBD vs S2	S1 vs S2
A/A	1.72 (1.66-1.78)	10.09 (9.72-10.5)	5.89 (5.73-6.11)	3.38 (3.04-3.60)	5.23 (4.65-6.07)	33.48 (27.9-37.6)
A/M	1.97 (1.85-2.26)	16.71 (15.0-18.4)	8.15 (7.86-8.68)	2.76 (2.15-3.48)	5.86 (4.58-6.28)	47.60 (41.3-53.7)
A/P	1.97 (1.90-2.04)	14.16 (13.4-14.6)	7.17 (6.95-7.36)	4.76 (4.08-5.46)	8.60 (7.85-10.5)	65.06 (59.0-69.6)
M/M	2.10 (2.06-2.12)	14.19 (13.7-14.5)	6.80 (6.61-6.93)	6.88 (6.24-7.55)	14.01 (12.7-15.1)	97.21 (92.1-100.9)
P/P	2.00 (1.96-2.04)	11.21 (11.0-11.5)	5.72 (5.64-5.78)	9.99 (9.48-10.4)	18.63 (17.8-20.0)	110.1 (104.2-114.1)
J	1.23 (0.97-1.61)	3.30 (2.72-4.18)	2.79 (2.35-4.06)	8.89 (3.71-13.3)	6.83 (4.70-22.35)	31.53 (15.6-38.7)

731 Ratios were calculated by dividing normalised MFI values for the two targets for all samples. RBD – receptor-
732 binding domain, S – full-length trimeric Spike protein. Median values are shown with 95% CI shown in brackets.
733 A/A – two dose AZD1222. A/M – first dose AZD1222, second dose mRNA-1273. A/P – first dose AZD1222,
734 second dose BNT162b2. M/M – two -dose mRNA-1273. P/P – two-dose BNT162b2. J – one-dose Ad26.CoV2.S.

735